Table 2.

Plasma concentration, SV2A occupancy, V _ND and IC ₅₀ for BRV or LEV

Cohort	ID	Drug	Study state	Dose, mg	Plasma conc., μg/mL	SV2A occupancy, %	V ND, mL/cm3	IC 50, μg/mL, individual	IC 50, μg/mL, global
2	5	BRV	Postdose	100	1.04	66	2.28	N/A	0.51
	6			100	0.98	70	3.06
	7			200	3.61	85	2.93
	8			200	2.94	84	2.36
	9			50	0.53	50	1.50
	5	LEV		1500	16.2	78	2.57	N/A	4.90
	6			1500	16.5	78	2.79
	7			1500	23.1	84	2.86
	8			1500	23.6	78	2.76
3	10	BRV	Postdose	100	1.63	74	3.25	0.54	0.45
			SS peak		2.91	86	3.05
			SS trough		1.7	76	3.80
	11		Postdose	50	0.98	72	3.73	0.44
			SS peak		1.61	76	3.78
			SS trough		0.84	64	3.97
	12		Postdose	100	1.23	80	3.08	0.32
			SS peak		2.53	87	2.90
			SS trough		1.43	82	3.24
	13		Postdose	50	0.91	67	3.04	0.50
			SS peak		1.99	78	2.71
			SS trough		1.22	70	2.89
	12	LEV	Postdose	250	3.65	58	4.01	N/A	3.58
	13		Postdose	600	10.7	68	2.51
	11		Postdose	250	4.25	52	2.10
2 and 3		BRV							0.46
		LEV							4.02

BRV, brivaracetam; conc., concentration; ID, subject identifier; LEV, levetiracetam; N/A, not available; SS, steady state.